Akebia Therapeutics' Vafseo adoption accelerates, but profitability remains distant amid Auryxia's decline. Read why AKBA ...
Jamie Dimon says the U.S. economy is resilient but risks remain—geopolitics, sticky inflation, deficits and high asset prices ...
Rivian (RIVN) raises $1.16B in equity for DOE loan/Georgia plant; analysts split on margins, R2 ramp and AV spend ahead of ...
Ballard Power Systems has emerged from the Trough of Disillusionment, with the hydrogen sector advancing towards the slope of ...
49m
JPMorgan Chase Q2 earnings beat as investment banking, equities fees surge, but expenses rise too
JPMorgan (JPM) stock dips as 2026 expense guidance rises, despite Q2 earnings and revenue beats and higher NII outlook.
The platform's transformation toward an all-ages audience unlocks new monetization avenues, making current concerns about ...
Artificial Intelligence is driving a new infrastructure and an internet revolution, demanding massive investment across ...
Organon (OGN) trades below Sun Pharma’s $14 cash bid; assess the 3.7% spread (~6% annualized) and downside risk if it ...
NextCure (NXTC) stock jumps as the company inks an all-stock merger deal with Avere Therapeutics plus a $320M private ...
Thrivent Asset Allocation Funds performed well in the 2nd quarter, with excess returns ranging from 2.47% to -0.09%. Read ...
Not all REITs are attractive despite the sector recovery—3 popular REITs face valuation and growth concerns. Read the full ...
During Q2 2026, Polen 5 Perspectives Small-Mid Growth Composite Portfolio returned 28.2% compared to the 24.0% return of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results